Literature DB >> 22740686

Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T cell proliferation.

Nikolaos Patsoukis1, Julia Brown, Victoria Petkova, Fang Liu, Lequn Li, Vassiliki A Boussiotis.   

Abstract

The receptor programmed death 1 (PD-1) inhibits T cell proliferation and plays a critical role in suppressing self-reactive T cells, and it also compromises antiviral and antitumor responses. To determine how PD-1 signaling inhibits T cell proliferation, we used human CD4(+) T cells to examine the effects of PD-1 signaling on the molecular control of the cell cycle. The ubiquitin ligase SCF(Skp2) degrades p27(kip1), an inhibitor of cyclin-dependent kinases (Cdks), and PD-1 blocked cell cycle progression through the G(1) phase by suppressing transcription of SKP2, which encodes a component of this ubiquitin ligase. Thus, in T cells stimulated through PD-1, Cdks were not activated, and two critical Cdk substrates were not phosphorylated. Activation of PD-1 inhibited phosphorylation of the retinoblastoma gene product, which suppressed expression of E2F target genes. PD-1 also inhibited phosphorylation of the transcription factor Smad3, which increased its activity. These events induced additional inhibitory checkpoints in the cell cycle by increasing the abundance of the G(1) phase inhibitor p15(INK4) and repressing the Cdk-activating phosphatase Cdc25A. PD-1 suppressed SKP2 transcription by inhibiting phosphoinositide 3-kinase-Akt and Ras-mitogen-activated and extracellular signal-regulated kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) signaling. Exposure of cells to the proliferation-promoting cytokine interleukin-2 restored activation of MEK-ERK signaling, but not Akt signaling, and only partially restored SKP2 expression. Thus, PD-1 blocks cell cycle progression and proliferation of T lymphocytes by affecting multiple regulators of the cell cycle.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22740686      PMCID: PMC5498435          DOI: 10.1126/scisignal.2002796

Source DB:  PubMed          Journal:  Sci Signal        ISSN: 1945-0877            Impact factor:   8.192


  74 in total

1.  Dual mode of degradation of Cdc25 A phosphatase.

Authors:  Maddalena Donzelli; Massimo Squatrito; Dvora Ganoth; Avram Hershko; Michele Pagano; Giulio F Draetta
Journal:  EMBO J       Date:  2002-09-16       Impact factor: 11.598

Review 2.  Living with or without cyclins and cyclin-dependent kinases.

Authors:  Charles J Sherr; James M Roberts
Journal:  Genes Dev       Date:  2004-11-15       Impact factor: 11.361

Review 3.  PD-1/PD-L1 pathway and T-cell exhaustion in chronic hepatitis virus infection.

Authors:  T Watanabe; A Bertoletti; T A Tanoto
Journal:  J Viral Hepat       Date:  2010-05-10       Impact factor: 3.728

4.  Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27.

Authors:  J Vlach; S Hennecke; B Amati
Journal:  EMBO J       Date:  1997-09-01       Impact factor: 11.598

5.  Tob is a negative regulator of activation that is expressed in anergic and quiescent T cells.

Authors:  D Tzachanis; G J Freeman; N Hirano; A A van Puijenbroek; M W Delfs; A Berezovskaya; L M Nadler; V A Boussiotis
Journal:  Nat Immunol       Date:  2001-12       Impact factor: 25.606

6.  Mechanism of activation of protein kinase B by insulin and IGF-1.

Authors:  D R Alessi; M Andjelkovic; B Caudwell; P Cron; N Morrice; P Cohen; B A Hemmings
Journal:  EMBO J       Date:  1996-12-02       Impact factor: 11.598

7.  Suppressor activity of anergic T cells induced by IL-10-treated human dendritic cells: association with IL-2- and CTLA-4-dependent G1 arrest of the cell cycle regulated by p27Kip1.

Authors:  Sebastian Kubsch; Edith Graulich; Jürgen Knop; Kerstin Steinbrink
Journal:  Eur J Immunol       Date:  2003-07       Impact factor: 5.532

8.  Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses.

Authors:  Frann Bennett; Deborah Luxenberg; Vincent Ling; I-Ming Wang; Kim Marquette; David Lowe; Nighat Khan; Geertruida Veldman; Kenneth A Jacobs; Viia E Valge-Archer; Mary Collins; Beatriz M Carreno
Journal:  J Immunol       Date:  2003-01-15       Impact factor: 5.422

9.  Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction.

Authors:  B M Burgering; P J Coffer
Journal:  Nature       Date:  1995-08-17       Impact factor: 49.962

10.  PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection.

Authors:  Constantinos Petrovas; Joseph P Casazza; Jason M Brenchley; David A Price; Emma Gostick; William C Adams; Melissa L Precopio; Timothy Schacker; Mario Roederer; Daniel C Douek; Richard A Koup
Journal:  J Exp Med       Date:  2006-09-05       Impact factor: 14.307

View more
  214 in total

Review 1.  Inhibitors of the PD-1 Pathway in Tumor Therapy.

Authors:  Martin W LaFleur; Yuki Muroyama; Charles G Drake; Arlene H Sharpe
Journal:  J Immunol       Date:  2018-01-15       Impact factor: 5.422

2.  Human Extrafollicular CD4+ Th Cells Help Memory B Cells Produce Igs.

Authors:  Sang Taek Kim; Jin-Young Choi; Begona Lainez; Vincent P Schulz; David E Karas; Eric D Baum; Jennifer Setlur; Patrick G Gallagher; Joe Craft
Journal:  J Immunol       Date:  2018-07-20       Impact factor: 5.422

3.  PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A.

Authors:  Nikolaos Patsoukis; Duygu Sari; Vassiliki A Boussiotis
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

Review 4.  A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma.

Authors:  Caroline E Nunes-Xavier; Javier C Angulo; Rafael Pulido; José I López
Journal:  Curr Urol Rep       Date:  2019-01-15       Impact factor: 3.092

5.  EF Hand Domain Family Member D2 Is Required for T Cell Cytotoxicity.

Authors:  Michael Peled; Matthew A Dragovich; Kieran Adam; Marianne Strazza; Anna S Tocheva; Irving E Vega; Adam Mor
Journal:  J Immunol       Date:  2018-10-01       Impact factor: 5.422

6.  Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma.

Authors:  Mohammad Atefi; Earl Avramis; Amanda Lassen; Deborah J L Wong; Lidia Robert; David Foulad; Michael Cerniglia; Bjoern Titz; Thinle Chodon; Thomas G Graeber; Begonya Comin-Anduix; Antoni Ribas
Journal:  Clin Cancer Res       Date:  2014-05-08       Impact factor: 12.531

7.  B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease.

Authors:  Ruishu Deng; Kaniel Cassady; Xiaofan Li; Sheng Yao; Mingfeng Zhang; Jeremy Racine; Jeffrey Lin; Lieping Chen; Defu Zeng
Journal:  J Immunol       Date:  2014-12-08       Impact factor: 5.422

Review 8.  Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease.

Authors:  John Attanasio; E John Wherry
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 9.  Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family.

Authors:  Frank A Schildberg; Sarah R Klein; Gordon J Freeman; Arlene H Sharpe
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

10.  Programmed Death-1 Inhibition of Phosphatidylinositol 3-Kinase/AKT/Mechanistic Target of Rapamycin Signaling Impairs Sarcoidosis CD4+ T Cell Proliferation.

Authors:  Lindsay J Celada; Joseph E Rotsinger; Anjuli Young; Guzel Shaginurova; Debresha Shelton; Charlene Hawkins; Wonder P Drake
Journal:  Am J Respir Cell Mol Biol       Date:  2017-01       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.